Why attend

As biologics programs scale, the cost of experimental work becomes significant, and the need for accurate tools that adapt to various scenarios to enable downstream decision-making from available information increases, helping save time and support confident progress.

In today’s era of high-throughput drug discovery, data grows faster than interpretation, and uncovering insightful relationships between sequence, structure, and lab results can guide programs more efficiently.

Integrating in silico analytics as antibody sequences are revealed helps preserve biological context early in discovery.

Without this integration:

• Clonal relationships become harder to track
• Epitope meaning shifts between assays
• Conserved targets appear less diverse than they are

This session shows how in vivo antibody discovery, computational lineage analysis, and epitope-level evidence help preserve biological context, uncover clonal and epitope diversity,  and support the visualization of biologically interpretable insights in a rapid and cost-effective manner.

Agenda

Presentation 1

Why biological evidence drifts as discovery scales

Speaker: Maria Giovanna Trovato, Director of Business Development

How biologics teams are managing increasing assay depth, data volume, and analytical complexity, and why maintaining traceable biological context has become essential for interpreting clonal and epitope-level evidence as programs move downstream.

Presentation 2

Clonal diversity and epitope coverage on a 100% conserved target

Speaker: Shuji Sato, VP of Innovative Solutions

A live, step-by-step walkthrough showing how in vivo discovery, lineage analysis, and epitope mapping illustrate diversity and coverage on a fully conserved target as data moves from sequence → clone → epitope resolution.

Who should attend

Teams working with challenging antibody targets, large clone panels, or multi-assay datasets where sequence, clonal, and epitope evidence must be integrated across computational and experimental platforms.

Format

Scientific overview + Q and A

When

📅 Date: March 18, 2026

🕙 Time: 10:00 AM CT | 11:00 AM ET | 4:00 PM CET

⏳ Duration: 60 minutes

Dr. Shuji Sato, PhD

Vice President of Innovative Solutions

Shuji Sato serves as the Vice President of Innovative Solutions for MindWalk with a focus on consistently delivering high value, technologically advanced scientific services to meet the objectives of the most challenging projects. He has over 20 years of experience in various R&D settings, including directing in vivo and in vitro antibody discovery and development teams at numerous biotech and pharma as well as in academia. He applies his broad knowledge in drug development to conceptualization and realization of projects and drives development of effective and innovative workflows.